Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study

BMC Cancer

Lucy Jankova³  Graham Robertson³  Charles Chan⁴  King L Tan⁷  Maija Kohonen-Corish⁶  Caroline L-S Fung⁷  Candice Clarke⁷  Betty P C Lin⁴  Mark Molloy¹  Pierre H Chapuis²  Les Bokey²  Owen F Dent²  Stephen J Clarke⁵ 

[1] Australian Proteome Analysis Facility and Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, NSW, 2109, Australia

[2] Department of Colorectal Surgery, Concord Hospital and Discipline of Surgery, The University of Sydney, Sydney, NSW, 2139, Australia

[3] Cancer Pharmacology Unit, ANZAC Research Institute, Concord Hospital, The University of Sydney, Sydney, NSW, 2139, Australia

[4] Department of Anatomical Pathology, Concord Hospital and Discipline of Pathology, The University of Sydney, Sydney, NSW, 2139, Australia

[5] Department of Medicine, Concord Hospital and Discipline of Medicine, The University of Sydney, Sydney, NSW, 2139, Australia

[6] Cancer Research Program, Garvan Institute of Medical Research and St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia

[7] Department of Anatomical Pathology, Concord Hospital, Sydney, NSW, 2139, Australia

关键词: Survival;    Adjuvant chemotherapy;    GST Pi;    Colon cancer;   

Others  :  1080411
DOI  :  10.1186/1471-2407-12-196

 received in 2011-12-24, accepted in 2012-05-11,  发布年份 2012

【 摘 要 】

Background

This study examined the association between overall survival and Glutathione S-transferase Pi (GST Pi) expression and genetic polymorphism in stage C colon cancer patients after resection alone versus resection plus 5-fluourouracil-based adjuvant chemotherapy.

Methods

Patients were drawn from a hospital registry of colorectal cancer resections. Those receiving chemotherapy after it was introduced in 1992 were compared with an age and sex matched control group from the preceding period. GST Pi expression was assessed by immunohistochemistry. Overall survival was analysed by the Kaplan-Meier method and Cox regression.

Results

From an initial 104 patients treated with chemotherapy and 104 matched controls, 26 were excluded because of non-informative immunohistochemistry, leaving 95 in the treated group and 87 controls. Survival did not differ significantly among patients with low GST Pi who did or did not receive chemotherapy and those with high GST Pi who received chemotherapy (lowest pair-wise p = 0.11) whereas patients with high GST Pi who did not receive chemotherapy experienced markedly poorer survival than any of the other three groups (all pair-wise p <0.01). This result was unaffected by GST Pi genotype.

Conclusion

Stage C colon cancer patients with low GST Pi did not benefit from 5-fluourouracil-based adjuvant chemotherapy whereas those with high GST Pi did.

【 授权许可】

   
2012 Jankova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Moscow J, Fairchild C, Madden MJ, Ransom DT, Wieand HS, O’Brien EE, Poplack DG, Cossman J, Meyers CE, Cowan KH: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumours. Cancer Res 1989, 49:1422-1428.
• [2]Doğru-Abbasoğlu S, Mutlu-Turkoğlu Ü, Türkoğlu S, Erbil Y, Barbaros U, Uysal M, Aykaç-Toker G: Glutathione S-transferase-pi in malignant tissues and plasma of human colorectal and gastric cancers. J Cancer Res Clin Oncol 2002, 128:91-95.
• [3]Mulder T, Verspaget H, Sier C, Roelofs HMJ, Ganesh S, Griffioen G, Peters WHM: Glutathione S-transferase π in colorectal tumours is predictive for overall survival. Cancer Res 1995, 55:2696-2702.
• [4]Sutoh I, Kohno H, Nakashima Y, Hishikawa Y, Tabara H, Tachibana M, Kubota H, Nagasue N: Concurrent expressions of metallothionein, glutathione S-transferase-π, and P-glycoprotein in colorectal cancers. Dis Colon Rectum 2000, 43:221-232.
• [5]Tan KL, Jankova L, Chan C, Fung CL-S, Clarke C, Lin PC, Robertson G, Molloy M, Chapuis PH, Bokey L, Dent OF, Clarke SJ: Clinicopathological correlates and prognostic significance of Glutathione S-Transferase Pi expression in 468 patients after potentially curative resection of node-positive colon cancer. Histopathology 2011, 59:1057-1070.
• [6]Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and stage III colon cancer: who benefits and by how much. J Clin Oncol 2004, 10:1797-1806.
• [7]Lee CK, Lord SJ, Coates AS, Simes RJ: Molecular biomarkers to individualise treatment: assessing the evidence. Med J Aust 2009, 190:631-636.
• [8]McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, Longley DB, Johnston PG: Prognostic significance of TRAIL signalling molecules in Stage II and III colorectal cancer. Clin Cancer Res 2011, 16:3442-3451.
• [9]Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004, 91:344-354.
• [10]Chen Y-C, Tzeng C-H, Chen P-M, Lin J-K, Lin T-C, Chen W-S, Jiang K-K, Wang H-S, Wang W-S: Influence of HSYP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2010, 101:530-535.
• [11]Funke S, Timofeeva M, Risch A, Hoffmeister M, Stegmaier C, Seiler CM, Brenner H, Chang-Claude J: Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 2010, 11:33-41.
• [12]Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F: Tryosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem 2009, 284:16979-16989.
• [13]McIlwain CC, Townsend DM, Tew KD: Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006, 25:1639-1648.
• [14]Rodriguez-Ramiro I, Ramos S, Bravo L, Goya L, Martin MA: Procyanidin B2 induces Nrf2 translocation and glutathione S-transferase P1 expression via ERKS and p38-MAPK pathways and protect human colonic cells against oxidative stress. Eur J Nutr 2011,  : . OnlineFirst 31 October 2011
• [15]Schumacker PT: Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
• [16]Hwang IT, Chung YM, Kim JJ, Chung JS, Kim BS, Kim HJ, Kim JS, Yoo YD: Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem Biophys Res Commun 2007, 359:304-310.
• [17]Santandreu FM, Valle A, Oliver J, Roca P: Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol Biochem 2011, 28:219-228.
• [18]Zimniak P, Nanduri B, Pikuła S, Bandorowicz-Pikuła J, Singhal SS, Srivastava SK, Awasthi S, Awasthi YC: Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994, 224:893-899.
• [19]Harries LW, Stubbins MJ, Forman D, Howard GCW, Wolf CR: Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997, 18:641-644.
• [20]Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz H-J: Association between GlutThione S-Transferase P1, P1 and M1 genetic polymorphism and survival in patients with metastatic colorectal cancer. JNCI 2002, 94:936-942.
• [21]Kim S-H, Kwon H-C, Oh SY, Lee DM, Lee S, Lee S-H, Roh M-S, Kim D-C, Park K-I, Choi H-J, Kim H-J: Prognostic value of ERCC1, Thymidylate Synthase and Glutathione S-Transferase π for 5-FU/Oxaliplatin chemotherapy in advanced colorectal cancer. Amer J Clin Oncol 2009, 32:38-43.
• [22]Jun L, Haiping Z, Beibei Y: Genetic polymorphisms of GST Pi related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly 2009, 139:274-278.
• [23]Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007, 25:1247-1254.
• [24]Etienne-Grimaldi M-C, Milano G, Maindrault-Gœbel F, Chibaudel B, Formento J-L, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms in colorectal cancer patients. Br J Clin Pharmacol 2010, 69:58-66.
• [25]Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JWR, Gelderblom H, Punt CJA, Guchelaar H-J: GST Pi Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 2008, 99:1316-1321.
• [26]Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, Robert J: Determination of ERCC2 Yys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 2007, 8:1693-1703.
• [27]Braun MS, Richman SD, Thompson L, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MKB, Seymour MT: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 2008, 26:2690-2698.
• [28]Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JWR, Punt CJA, Guchelaar H-J: Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy of toxicity in advanced colorectal cancer patients. Eur J Cancer 2009, 45:572-578.
• [29]Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, Elder JB, Elder J, Smith V, Strange RC, Fryer AA: Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 2006, 28:231-236.
• [30]Jones BA, Christensen AR, Wise JP, Yu H: Glutathione S-transferase polymorphisms and survival in African-American and white colorectal cancer patients. Cancer Epidemiol 2009, 33:249-256.
• [31]Newland RC, Chapuis PH, Pheils MT, Macpherson JG: The relationship of survival to staging and grading of colorectal carcinoma. A prospective study of 503 cases. Cancer 1981, 47(Newland RC):1424-1429.
• [32]Newland RC, Chapuis PH, Smyth EJ: The prognostic value of substaging in colorectal carcinoma. A prospective study of 1117 cases with standardized pathology. Cancer 1987, 60:852-857.
• [33]Bokey EL, Chapuis PH, Dent OF, Mander BJ, Bissett IP, Newland RC: Surgical technique and survival in patients having a curative resection for colon cancer. Dis Colon Rectum 2003, 46:860-866.
• [34]Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Crook JE, Mailliard JA, Laurie JA, Tschetter LK: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 10:1407-1418.
• [35]Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM: The modulation of flurourocil with leucovorin in metastatic colorectal cancer; a prospective randomized phase III trial. J Clin Oncol 1989, 10:1419-1426.
• [36]Chapuis PH, Bokey EL, Clarke S, Beale P, Dent OF: Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. ANZ J Surg 2009, 79:685-692.
• [37]Koo JH, Leong WL: Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. J Gastroenterol Hepatol 2010, 25:33-42.
• [38]Davis NC, Newland RC: Terminology and classification of colorectal adenocarcinoma: the Australian Clinico-pathological Staging System. Aust NZ J Surg 1983, 53:211-221.
• [39]Darakhshan A, Lin BP, Chan C, Chapuis PH, Dent OF, Bokey EL: Correlates and outcomes of tumour adherence in resected colonic and rectal cancers. Ann Surg 2008, 247:650-658.
• [40]Keshava A, Chapuis PH, Chan C, Lin BPC, Bokey EL, Dent O: The significance of involvement of a free serosal surface for recurrence and survival following resection of clinicopathological stage B and C rectal cancer. Colorectal Dis 2007, 9:609-618.
• [41]Gabriel WB, Dukes C, Bussey HJR: Lymphatic spread in cancer of the rectum. Br J Surg 1935, 23:395-413.
• [42]Fielding LP, Arsenault PA, Chapuis PH, Gathright B, Hardcastle JD, Hermanek P, Jass JR, Newland RC: Clinicopathological staging for colorectal cancer: An international documentation (IDS) and an international comprehensive anatomical terminology (ICAT). J Gastroenterol Hepatol 1991, 6:325-344.
• [43]Chan C, Jankova L, Fung C, Clarke C, Robertosn G, Chapuis PH, Bokey L, Lin BPC, Dent OF, Clarke S: Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. Am J Surg Path 2010, 34:656-666.
• [44]Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY, Dent OF, Dhillon VS, Trent RJ, Chapuis PH, Bokey EL: Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005, 23:2318-2324.
• [45]Kohonen-Corish MR, Sigglekow ND, Susanto J, Chapuis PH, Bokey EL, Dent OF, Chan C, Lin BP, Seng TJ, Laird PW, Young J, Leggett BA, Jass JR, Sutherland RL: Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene 2007, 26:4435-4441.